SCHEMBL44109

SCHEMBL44109

COc1ccc(F)cc1CCN

nearest known ligand 0.68

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 4/20 0.68
ADRA1A P35348 1/20 0.68
SLC6A2 P23975 7/20 0.60
SLC6A4 P31645 7/20 0.60
SLC6A3 Q01959 7/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL34462923 0.98 TAAR1 (0.66) TAAR1ADRA1ASLC6A2SLC6A4SLC6A3
SCHEMBL26622106 0.87 TAAR1 (0.54) TAAR1ADRA1ASLC6A2SLC6A4SLC6A3
SCHEMBL34462888 0.87 TAAR1 (0.61) TAAR1ADRA1A
SCHEMBL3717229 0.87 TAAR1 (0.61) TAAR1ADRA1A
SCHEMBL2447300 0.84 SLC6A2 (0.54) TAAR1ADRA1ASLC6A2SLC6A4SLC6A3
SCHEMBL31119318 0.84 SLC6A2 (0.54) TAAR1ADRA1ASLC6A2SLC6A4SLC6A3
SCHEMBL12844526 0.82 HMGCR (0.53) TAAR1ADRA1ASLC6A2SLC6A4SLC6A3
Hydrochloric Acid SCHEMBL5597852 0.82 SLC6A2 (0.53) TAAR1ADRA1ASLC6A2SLC6A4SLC6A3
SCHEMBL27756766 0.82 TAAR1 (0.70) TAAR1ADRA1A
SCHEMBL18894529 0.81 SLC6A2 (0.49) TAAR1ADRA1ASLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2744908-A1 ENZYMATIC SYNTHESIS OF OPTICALLY ACTIVE CHIRAL AMINES Embio Limited (IN) 2014-06-25 EP claimed
WO-2013024453-A1 ENZYMATIC SYNTHESIS OF OPTICALLY ACTIVE CHIRAL AMINES EMBIO LIMITED (IN) 2013-02-21 WO claimed
EP-4725942-A1 COMPOUNDS ACTIVE ON CYCLIN D1 PATHWAY AND THEIR USE Sibylla Biotech S.p.A. (IT) 2026-04-15 EP disclosed
WO-2025089147-A1 HERBICIDAL COMPOSITION 株式会社エス・ディー・エス バイオテック 2025-05-01 WO disclosed
EP-3724324-A1 CARBOXYESTERASE BIOCATALYSTS GlaxoSmithKline Intellectual Property Development Ltd (GB) 2020-10-21 EP disclosed
WO-2019116311-A1 CARBOXYESTERASE BIOCATALYSTS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-06-20 WO disclosed
US-10053428-B2 5-aminotetrahydroquinoline-2-carboxylic acids and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-08-21 US disclosed
US-20170260139-A1 NOVEL 5-AMINOTETRAHYDROQUINOLINE-2-CARBOXYLIC ACIDS AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-09-14 US disclosed
US-9688636-B2 5-aminotetrahydroquinoline-2-carboxylic acids and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-06-27 US disclosed
EP-2875003-B1 NEW 5-AMINOTETRAHYDROQUINOLINE-2-CARBOXYLIC ACIDS UND THEIR USE Bayer Pharma AG (DE) 2016-11-16 EP disclosed
EP-2961838-A1 IMMOBILIZED TRANSAMINASES AND PROCESS FOR MAKING AND USING IMMOBILIZED TRANSAMINASE Merck Sharp & Dohme Corp. (US) 2016-01-06 EP disclosed
WO-2006063336-A2 THERMOSTABLE OMEGA-TRANSAMINASES CAMBREX NORTH BRUNSWICK, INC. (US) 2006-06-15 WO disclosed
US-20060094769-A1 Novel aminodicarboxylic acid derivatives having pharmaceutical properties BAYER AKTIENGESELLSCHAFT (DE) 2006-05-04 US disclosed
EP-1075534-B8 IMPROVEMENTS IN THE ENZYMATIC SYNTHESIS OF CHIRAL AMINES CELGRO (US) 2005-07-06 EP disclosed
EP-1216225-B1 NOVEL DERIVATIVES OF DICARBOXYLIC ACID HAVING PHARMACEUTICAL PROPERTIES BAYER HEALTHCARE AG (DE) 2005-07-06 EP disclosed
EP-1075534-A4 IMPROVEMENTS IN THE ENZYMATIC SYNTHESIS OF CHIRAL AMINES CELGRO (US) 2003-07-09 EP disclosed
EP-1216225-A2 NOVEL DERIVATIVES OF DICARBOXYLIC ACID HAVING PHARMACEUTICAL PROPERTIES Bayer Aktiengesellschaft (DE) 2002-06-26 EP disclosed
WO-2001019780-A2 NOVEL DERIVATIVES OF DICARBOXYLIC ACID HAVING PHARMACEUTICAL PROPERTIES BAYER AKTIENGESELLSCHAFT (DE) 2001-03-22 WO disclosed
EP-1075534-A1 IMPROVEMENTS IN THE ENZYMATIC SYNTHESIS OF CHIRAL AMINES Celgro (US) 2001-02-14 EP disclosed
WO-1999046398-A1 IMPROVEMENTS IN THE ENZYMATIC SYNTHESIS OF CHIRAL AMINES CELGRO (US) 1999-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10053428-B2 5-aminotetrahydroquinoline-2-carboxylic acids and their use TNNT2, TNNI3, FABP3 TAAR1 1785/4885ADRA1A 107/4885SLC6A2 841/4885
US-20170260139-A1 NOVEL 5-AMINOTETRAHYDROQUINOLINE-2-CARBOXYLIC ACIDS AND THEIR USE TNNT2, TNNI3, FABP3 TAAR1 1534/4885ADRA1A 84/4885SLC6A2 866/4885
US-20060094769-A1 Novel aminodicarboxylic acid derivatives having pharmaceutical properties DDC, AADAT, PTGIS TAAR1 1839/4885ADRA1A 855/4885SLC6A2 2554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.